Advanced Renal Cell Carcinoma Clinical Trials

72 clinical trials for Advanced Renal Cell Carcinoma across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom — RECRUITING · PHASE1
• A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) — RECRUITING · PHASE2
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours — RECRUITING · PHASE1
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) — RECRUITING · PHASE1
• Sitagliptin With Pembro in RCC and Melanoma — RECRUITING · PHASE1
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — RECRUITING · PHASE1
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program — RECRUITING · PHASE2
• Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC — RECRUITING · PHASE2
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer — RECRUITING · PHASE2
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer — RECRUITING · PHASE1
• Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors — RECRUITING · PHASE1
• Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer — NOT_YET_RECRUITING · PHASE1
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study — ACTIVE_NOT_RECRUITING · PHASE2
• Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma — SUSPENDED · PHASE1
• Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. — ACTIVE_NOT_RECRUITING
• The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors — SUSPENDED · PHASE1
• PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC — NOT_YET_RECRUITING · PHASE1
• A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults — COMPLETED
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) — COMPLETED · PHASE3
• Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma — COMPLETED · NA
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies — TERMINATED · PHASE1
• Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma — NOT_YET_RECRUITING · NA
• CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial — SUSPENDED · PHASE2
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
• Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma — TERMINATED · PHASE1
• PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer — ACTIVE_NOT_RECRUITING · NA
• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma — TERMINATED · PHASE1
• Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) — TERMINATED · PHASE2
• Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients — COMPLETED
• RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy — NOT_YET_RECRUITING · PHASE2
• Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Study of ST-1898 in Advanced Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy — NOT_YET_RECRUITING · PHASE1
• A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma — COMPLETED · PHASE2
• Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination — COMPLETED
• IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients — TERMINATED · PHASE1
• CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer — COMPLETED · PHASE1
• Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea — COMPLETED
• An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK — COMPLETED
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma — TERMINATED · PHASE2
• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment — COMPLETED · PHASE2
• A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France. — COMPLETED
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma — COMPLETED · PHASE2

Refine this search